Theravectys Raises €14.7M

Theravectys, a Paris, France-based biotechnology company specialized in developing vaccines using lentiviral vector technology, raised €14.7m (approximately US$20m) in funding.

Backers included Tethys, the holding company owned by the Bettencourt family, Financière IDAT (Philippe ODDO), FGP Capital and other private investors.

The company intends to use the funds to accelerate the development of its vaccines platform and implement international collaborations.

Led by Jean-Pierre Kinet, Chairman, and Renaud Vaillant, Chief Executive Officer, Theravectys is developing a new generation of vaccines based on lentiviral vector technology from research at Institut Pasteur, which is expected to enable the prevention or effective treatment of viral diseases (HIV), bacterial or parasitic diseases, cancers, etc.



Join the discussion